Provision of Bordetella-Free Baboons for Pertussis Infection and Vaccination Studies
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
FOOD AND DRUG ADMINISTRATION
Contract Value
Not provided
Codes & Classification
Solicitation Number
75F40126Q00204
NAICS
112990 - All Other Animal Production
Classification Code
8820
Additional Details
Documents2
The Food and Drug Administration (FDA), under the Department of Health and Human Services, has issued a combined synopsis/solicitation for the provision of Bordetella-free baboons to support critical pertussis infection and vaccination studies. This procurement, identified under solicitation number 75F40126Q00204, seeks to acquire and deliver twenty baboons that are certified free of Bordetella infection. The animals will be used by the FDA’s Center for Biologics Evaluation and Research (CBER) in Silver Spring, Maryland, to advance research into pertussis (whooping cough), a highly contagious and potentially life-threatening respiratory disease caused by Bordetella pertussis.
The primary objective of this procurement is to facilitate the refinement of the baboon model for pertussis, which is currently the only animal model that accurately replicates the disease as it occurs in humans. The FDA’s research aims to deepen the understanding of why current public health measures and licensed vaccines have not fully controlled pertussis outbreaks. By establishing infection in baboons through natural transmission, the study will enable a more nuanced evaluation of the differences between acellular pertussis vaccines—which have shown limitations in preventing infection—and whole cell vaccines, which have demonstrated greater efficacy in reducing infection rates.
Key requirements for this solicitation include the provision of twenty baboons that are confirmed to be free of Bordetella infection. The animals must be suitable for use in controlled infection and vaccination studies, ensuring the integrity and reliability of the research outcomes. The successful contractor will be responsible for the timely delivery of these animals to the FDA’s research facility in Silver Spring, Maryland.
This opportunity is classified under NAICS code 112990 (All Other Animal Production), with a Product Service Code of 8820. There are no set-aside restrictions associated with this procurement, making it open to all qualified vendors capable of meeting the specified requirements. The solicitation is active, with a response deadline of July 10, 2026.
Interested parties should note that the procurement is managed by the FDA’s contracting office, and all inquiries or submissions should be directed to the designated contacts: David Kramer ([email protected]) and Nick Sartain ([email protected]). Additional details, including any amendments and attachments, are available through the official SAM.gov opportunity listing at https://sam.gov/opp/a3a0d837a54747d39a3893ac8c767908/view.
Contractors considering this opportunity should have demonstrated experience in the production and supply of research-grade nonhuman primates, with robust health screening protocols to ensure animals are free from Bordetella and suitable for infectious disease research. The successful execution of this contract will directly support the FDA’s mission to improve public health outcomes through enhanced understanding of pertussis pathogenesis and vaccine efficacy.